# Neurology Medical Scenarios

## Scenario 1: Acute Ischemic Stroke

### Patient Profile
- **Name:** William Rodriguez
- **Age:** 72 years
- **Gender:** Male
- **Weight:** 175 lbs (79 kg)
- **Height:** 5'8" (173 cm)
- **BMI:** 25.7
- **Occupation:** Retired mechanic

### Medical History
- **Primary:** Acute ischemic stroke (middle cerebral artery territory)
- **Medical History:** 
  - Atrial fibrillation (2 years)
  - Hypertension (15 years)
  - Type 2 diabetes (8 years)
  - Hyperlipidemia (10 years)
- **Medications:** Warfarin 5mg daily, Metoprolol 50mg BID, Metformin 1000mg BID, Atorvastatin 40mg daily
- **Social History:** Former smoker (quit 10 years ago, 30 pack-year history)

### Chief Complaint
"My wife says I was talking strangely and my face looked droopy. She couldn't understand what I was saying."

### Timeline of Events
- **9:30 AM:** Patient found by wife, unable to speak clearly
- **9:35 AM:** EMS called (last known normal time: 9:00 AM)
- **9:50 AM:** EMS arrival, FAST exam positive (Face droop, Arm weakness, Speech difficulty, Time to call 911)
- **10:05 AM:** Hospital arrival

### Initial Assessment
- **Vital Signs:** BP 185/100 mmHg, HR 95 (irregular), RR 18, Temp 98.8°F
- **Glucose:** 145 mg/dL
- **NIHSS Score:** 14 (moderate stroke severity)

### Physical Examination
- **General:** Alert, oriented to person only
- **Neurological:**
  - **Cranial Nerves:** Right facial droop (upper and lower face)
  - **Motor:** Left hemiparesis (5/5 right side, 2/5 left side)
  - **Sensory:** Left hemisensory loss
  - **Speech:** Moderate dysarthria, good comprehension
  - **Reflexes:** Hyperreflexia on left side

### Diagnostic Results
- **Non-contrast Head CT:** No acute hemorrhage, early ischemic changes in right MCA territory
- **CTA Head/Neck:** Right MCA occlusion, no significant carotid stenosis
- **ECG:** Atrial fibrillation with rapid ventricular response
- **Labs:** INR 2.1 (therapeutic), CBC normal, CMP normal

### Clinical Decision Points

#### Time-Sensitive Decisions
1. **Last Known Normal:** 9:00 AM (within 4.5-hour window for tPA)
2. **IV tPA Eligibility:**
   - Time: Within 4.5 hours ✓
   - Blood pressure: Systolic <185 mmHg ✓
   - No hemorrhage on CT ✓
   - INR therapeutic (2.1) - caution but acceptable

#### Endovascular Therapy Consideration
- **Large vessel occlusion:** Right MCA occlusion
- **Time window:** Up to 24 hours with perfusion imaging
- **NIHSS score:** 14 (eligible, typically ≥6)

#### Contraindications to tPA
- **Active bleeding:** None identified
- **Recent surgery:** None
- **Intracranial neoplasm:** None
- **Hemorrhagic stroke history:** None

### Treatment Plan

#### Immediate Actions (First Hour)
1. **IV Thrombolysis:**
   - Alteplase 0.9 mg/kg (maximum 90 mg)
   - 10% as IV bolus over 1 minute
   - 90% as continuous infusion over 60 minutes
   - Monitoring in stroke unit

2. **Blood Pressure Management:**
   - Target: <185/110 mmHg before tPA
   - Labetalol 10-20mg IV if needed
   - Monitor for reperfusion injury

3. **Neurological Monitoring:**
   - NIHSS every 15 minutes for 2 hours
   - Continuous cardiac monitoring
   - Blood pressure every 15 minutes

#### Endovascular Therapy
1. **Mechanical Thrombectomy:**
   - Door-to-groin time: <90 minutes
   - Target: TICI 2b-3 reperfusion
   - Post-procedure monitoring in ICU

#### Secondary Prevention
1. **Antiplatelet Therapy:**
   - Aspirin 325mg immediately post-tPA (after 24 hours)
   - Dual antiplatelet therapy (DAPT) for 21-90 days

2. **Anticoagulation:**
   - Continue warfarin (INR target 2.0-3.0)
   - Consider DOAC if patient prefers

3. **Risk Factor Management:**
   - Atorvastatin 80mg daily
   - Blood pressure target <130/80 mmHg
   - Diabetes management optimization

### Complications Monitoring
1. **Hemorrhagic Transformation:**
   - Repeat CT at 24 hours
   - Monitor neurological changes
   - Blood pressure control

2. **Cerebral Edema:**
   - Monitor for increased ICP signs
   - Mannitol if needed

3. **Aspiration Risk:**
   - NPO initially
   - Swallow evaluation before feeding

### Prognosis and Goals
- **6-month mRS target:** 0-2 (good outcome)
- **Expected improvement:** 40-50% of patients achieve functional independence
- **Rehabilitation:** Physical, occupational, speech therapy

### Learning Objectives
- Apply rapid stroke assessment protocols
- Calculate NIHSS score accurately
- Understand IV thrombolysis eligibility criteria
- Coordinate endovascular therapy
- Manage stroke complications

---

## Scenario 2: Status Epilepticus

### Patient Profile
- **Name:** Sarah Kim
- **Age:** 34 years
- **Gender:** Female
- **Weight:** 125 lbs (57 kg)
- **Height:** 5'5" (165 cm)
- **BMI:** 20.6
- **Occupation:** Librarian

### Medical History
- **Primary:** Idiopathic generalized epilepsy
- **Seizure History:** Well-controlled on medication for 8 years
- **Current Medications:** Lamotrigine 200mg BID
- **Social History:** Non-smoker, occasional alcohol use
- **Family History:** Brother with epilepsy

### Chief Complaint
"My husband says I've been having seizures continuously for the past 20 minutes and I won't wake up between them."

### Clinical Presentation
- **Event Timeline:**
  - **7:45 PM:** Generalized tonic-clonic seizure observed by husband
  - **8:00 PM:** Patient appears to recover briefly, then another seizure
  - **8:05 PM:** Continuous seizure activity, minimal recovery

### Physical Examination
- **Vital Signs:** BP 160/95 mmHg, HR 120, RR 28, Temp 102.1°F (38.9°C)
- **General:** Continuous generalized tonic-clonic movements
- **Pupils:** Dilated, reactive
- **Breathing:** Labored, cyanotic

### Clinical Decision Points

#### Status Epilepticus Definition
- **Seizure duration >5 minutes** or
- **Recurrent seizures without return to baseline** between episodes
- **Requires immediate treatment** to prevent permanent brain damage

#### Initial Treatment Priorities
1. **Airway, Breathing, Circulation**
2. **Rapid seizure termination**
3. **Treat underlying cause**
4. **Prevent complications**

### Treatment Protocol

#### Immediate Actions (0-5 minutes)
1. **Airway Management:**
   - Oxygen supplementation
   - Suction ready
   - Position for airway protection

2. **First-Line Treatment:**
   - Lorazepam 4mg IV (0.1 mg/kg)
   - If no IV access: Midazolam 10mg IM

#### Second-Line Treatment (5-20 minutes)
1. **Fosphenytoin:**
   - 20 mg/kg IV (max 1500 mg)
   - Rate: 150 mg/min IV

2. **Alternative:** Valproic acid
   - 40 mg/kg IV (max 3000 mg)
   - Rate: 20 mg/min IV

#### Refractory Status (20-60 minutes)
1. **Third-Line Treatment:**
   - Propofol: 2 mg/kg IV bolus, then infusion 2-10 mg/kg/hr
   - OR
   - Midazolam: 0.2 mg/kg IV bolus, then infusion 0.05-2 mg/kg/hr

2. **Intubation Considerations:**
   - Failed seizure control
   - Respiratory compromise
   - Neuromuscular blockade needed

### Etiological Workup
1. **Infectious:** 
   - Blood cultures
   - Lumbar puncture (if safe)
   - CT head before LP

2. **Metabolic:**
   - Glucose, electrolytes
   - Toxicology screen
   - Arterial blood gas

3. **Structural:**
   - CT head (emergent)
   - MRI brain (post-stabilization)

### Complications Management
1. **Hyperthermia:**
   - Cooling measures
   - Acetaminophen
   - Monitor for rhabdomyolysis

2. **Metabolic Acidosis:**
   - Monitor ABG
   - Correct underlying cause

3. **Pulmonary Edema:**
   - Diuretics if needed
   - Monitor respiratory status

### Long-term Management
1. **Medication Optimization:**
   - Lamotrigine dose adjustment
   - Consider additional AED
   - Therapeutic drug monitoring

2. **Patient Education:**
   - Medication compliance
   - Seizure precautions
   - When to call EMS

### Prognosis
- **Status epilepticus mortality:** 5-10%
- **Risk factors for poor outcome:** Prolonged duration, delayed treatment, older age
- **Neurological sequelae:** Depends on underlying cause

### Learning Objectives
- Recognize status epilepticus
- Apply staged treatment protocol
- Manage airway and breathing
- Treat underlying causes
- Prevent complications

---

## Scenario 3: Parkinson's Disease with Motor Fluctuations

### Patient Profile
- **Name:** Robert Anderson
- **Age:** 68 years
- **Gender:** Male
- **Weight:** 160 lbs (73 kg)
- **Height:** 5'7" (170 cm)
- **BMI:** 24.8
- **Occupation:** Retired engineer

### Medical History
- **Primary:** Parkinson's disease (12 years)
- ** Hoehn & Yahr Stage:** 3 (moderate bilateral disease)
- **Medical History:** Hypertension, depression
- **Medications:** 
  - Carbidopa/levodopa 25/100mg TID
  - Pramipexole 1mg TID
  - Selegiline 5mg BID
  - Sertraline 50mg daily

### Chief Complaint
"My medications aren't working as well as they used to. I have these 'off' periods where I can barely move, and my tremors are getting worse."

### Clinical Timeline
- **Initial Diagnosis:** 12 years ago (age 56)
- **3 years ago:** Started experiencing motor fluctuations
- **1 year ago:** Wearing-off phenomena noted
- **6 months ago:** Added pramipexole
- **Current:** Severe "off" periods, dyskinesias

### Physical Examination
- **Vital Signs:** Stable
- **General:** Bradykinesia during "off" periods
- **Motor Examination:**
  - **Rigidity:** Cogwheel rigidity bilaterally
  - **Tremor:** Resting tremor (4-6 Hz), right hand predominant
  - **Bradykinesia:** Slowed movements, reduced arm swing
  - **Postural Instability:** Mild retropulsion

### Motor Fluctuations Assessment
1. **"On" Time:** 50% of waking hours
2. **"Off" Time:** 50% of waking hours
3. **Dyskinesias:** Moderate, affecting daily activities
4. **Dose Failure:** Occurs 1-2 hours before next dose

### Diagnostic Tools
1. **UPDRS (Unified Parkinson's Disease Rating Scale):**
   - Part II (Activities of Daily Living): 28/52
   - Part III (Motor Examination): 31/108
   - Part IV (Complications): 12/32

2. **PD Questionnaire-39 (PDQ-39):** 
   - Mobility domain: Most affected
   - Daily activities significantly impacted

### Clinical Decision Points

#### Motor Fluctuation Patterns
1. **Wearing-Off Phenomenon:**
   - Symptoms return before next dose
   - Predictable timing
   - Responsive to dose adjustment

2. **Delayed On:**
   - Slow onset of medication effect
   - Related to gastric emptying

3. **Dose Failure:**
   - Inadequate response to medication
   - Requires higher doses or frequency

#### Treatment Adjustments
1. **Levodopa Optimization:**
   - Increase frequency (TID to QID)
   - Consider controlled-release formulation

2. **Adjunct Therapies:**
   - MAO-B inhibitor (selegiline)
   - Dopamine agonist (pramipexole)
   - COMT inhibitor consideration

### Treatment Plan

#### Immediate Optimizations
1. **Levodopa Adjustment:**
   - Increase to 25/100mg QID
   - Consider carbidopa/levodopa 50/200mg CR at bedtime

2. **Adjunct Therapy Review:**
   - Continue pramipexole
   - Add entacapone 200mg with each levodopa dose

#### Advanced Therapies (Future Considerations)
1. **Deep Brain Stimulation (DBS):**
   - Age <70 years
   - Good response to levodopa
   - Motor fluctuations not controlled with medications

2. **Continuous Levodopa Infusion:**
   - Duodopa pump system
   - For severe motor fluctuations

#### Symptom-Specific Management
1. **Tremor:**
   - Consider amantadine for tremor-dominant PD
   - DBS targeting ventrolateral thalamus

2. **Postural Instability:**
   - Physical therapy focus
   - Fall prevention strategies

### Lifestyle Modifications
1. **Exercise:**
   - Regular aerobic exercise
   - Tai Chi or yoga for balance
   - Speech therapy for voice changes

2. **Nutrition:**
   - High-protein meal timing
   - Adequate fiber for constipation
   - Consider protein redistribution diet

### Monitoring and Follow-up
1. **Motor Symptoms:**
   - Motor diaries (on/off periods)
   - UPDRS scoring every 3-6 months

2. **Medication Side Effects:**
   - Dyskinesia assessment
   - Neuropsychiatric symptoms
   - Sleep disturbances

### Prognosis and Goals
- **Disease Progression:** Slow progression typical
- **Goal:** Maintain functional independence
- **Life Expectancy:** Near normal with good management

### Learning Objectives
- Assess motor fluctuations in Parkinson's disease
- Apply levodopa optimization principles
- Understand advanced therapy options
- Manage non-motor symptoms
- Coordinate multidisciplinary care

---

## Additional Neurology Scenarios

### Migraine with Aura
- **Patient:** 28-year-old female with recurrent headaches
- **Key points:** Aura characteristics, preventive therapy, acute management
- **Learning objectives:** Headache classification and treatment

### Multiple Sclerosis Relapse
- **Patient:** 35-year-old male with optic neuritis and new symptoms
- **Key points:** Disease-modifying therapy, relapse management
- **Learning objectives:** Demyelinating disease management

### Alzheimer's Disease
- **Patient:** 75-year-old female with progressive memory loss
- **Key points:** Cognitive assessment, cholinesterase inhibitors
- **Learning objectives:** Dementia management principles

---

## References and Guidelines

### Primary Guidelines
1. **American Academy of Neurology Practice Guidelines**
2. **European Stroke Organisation Guidelines (ESO)**
3. **International League Against Epilepsy (ILAE) Guidelines**
4. **Movement Disorder Society Evidence-Based Medicine Review**

### Key Evidence Sources
- NINDS tPA stroke trials
- EAST trial (endovascular therapy)
- Status epilepticus protocols
- Parkinson's disease movement disorder studies

### Quality Metrics
- Door-to-needle time for stroke
- Appropriate tPA administration rates
- Seizure recurrence prevention
- Stroke outcome measures (modified Rankin Scale)

---

*Note: All scenarios are fictional and created for educational purposes. Patient information has been de-identified and modified for demonstration.*